Brazilian descriptive study of 104 consecutive real-world migraine patients treated with monoclonal antibodies

References

• GBD. Disease and injury incidence and prevalence collaborators (2017) global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2016;390:1211–1259.
   Web of Science ®Google Scholar
• González-Hernández A, Marichal-Cancino BA, MaassenVanDenBrink A, et al. Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin Drug Metabol Toxicol. 2018;14(1):25–41.
   PubMed Web of Science ®Google Scholar
• Tso AR, Goadsby PJ. Anti-CGRP monoclonal antibodies: the next era of migraine prevention? Curr Treat Options Neurol. 2017;19(8):27.
   PubMed Web of Science ®Google Scholar
• Messina R, Goadsby PJ. CGRP – a target for acute therapy in migraine: clinical data. Cephalalgia. 2019;39(3):420–427.
   PubMed Web of Science ®Google Scholar
• Waschek JA, Baca SM, Akerman S. PACAP and migraine headache: immunomodulation of neural circuits in autonomic ganglia and brain parenchyma. J Headache Pain. 2018;19(1):23.
   PubMed Web of Science ®Google Scholar
• McLatchieL M, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998;393(6683):333–339.
   PubMed Web of Science ®Google Scholar
• Tepper SJ. History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment. Headache. 2018;58:238–275.
   PubMed Web of Science ®Google Scholar
• Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014;83(11):958–966.
   PubMed Web of Science ®Google Scholar
• Ho AP, Dahlof CG, Silberstein SD, et al. Randomized controlled trial of telcagepant over four migraine attacks. Cephalalgia. 2010;30(12):1443–1445.
   PubMed Web of Science ®Google Scholar
• Loder EW, Robbins MS. Monoclonal antibodies for migraine prevention. Progress, but not a panacea. JAMA. 2018;319(19):1985–1987.
   PubMed Web of Science ®Google Scholar
• Headache Classification Subcommittee of the International Headache Society. Headache classification committee of the International Headache Society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
   Web of Science ®Google Scholar
• Dodick D. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia. 2019;39(3):445–458.
   PubMed Web of Science ®Google Scholar
• Ashina M, Goadsby PJ, Reuter U, et al. Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021;28(5):1716–1725.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Walter S, Rapoport A. Fremanezumab as a preventive treatment for episodic and chronic migraine. Expert Rev Neurother. 2019;19(8):719–728.
   PubMed Web of Science ®Google Scholar
• Krymchantowski AV, Krymchantowski AG, Jevoux CC. Real-world experience with new migraine treatments in Brazil. Avan Med. 2021;1:24–29.
   Google Scholar
• Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123–2132.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026–1037.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Dodick DW, Rapoport A, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high- frequency episodic migraine: a multicenter, randomized, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14(11):1081–1090.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized controlled trial. JAMA. 2018;319(19):1999–2008.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Edvinsson L, Rapoport A, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomized, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14(11):1091–1100.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–2122.
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–1088.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–1454.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13(11):1100–1107.
   PubMed Web of Science ®Google Scholar
• Saper JR, Lipton RB, Kudrow DB, et al. A phase 3, randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of eptinezumab in frequent episodic migraine prevention: primary results of the PROMISE 1 (prevention of migraine via intravenous eptinezumab safety and efficacy 1) trial. PO-01-194. Cephalalgia. 2017;37:337.
   Web of Science ®Google Scholar
• Lattanzi S, Brigo F, Trinka E, et al. Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety. Drugs. 2019;79(4):417–431.
   PubMed Web of Science ®Google Scholar
• Pellesi L, Al-Karagholi -MA-M, Chaudhry BA, et al. Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers. Cephalalgia. 2020;40(11):1212–1223.
   PubMed Web of Science ®Google Scholar
• Pellesi L, Al-Karagholi -MA-M, De Icco R, et al. Effect of vasoactive intestinal polypeptide on development of migraine headaches: a randomized clinical trial. JAMA Network Open. 2021;4(8):e2118543.
   PubMed Web of Science ®Google Scholar
• Robblee J, Devick KL, Mendez N, et al. Real-world patient experience with erenumab for the preventive treatment of migraine. Headache. 2020;60(9):2014–2025.
   PubMed Web of Science ®Google Scholar
• Caronna E, Gallardo VJ, Alpuente A, et al. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. J Headache Pain. 2021;22(1):120.
   PubMed Web of Science ®Google Scholar
• Vandervorst F, Van Deun L, Van Dycke A, et al. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 2021;22(1):128.
   PubMed Web of Science ®Google Scholar
• McAllister P, Lamerato L, Krasenbaum LJ, et al. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States. J Headache Pain. 2021;22(1):156.
   PubMed Web of Science ®Google Scholar
• Terhart M, Mecklenburg J, Neeb L, et al. Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies. J Headache Pain. 2021;22(1):158.
   PubMed Web of Science ®Google Scholar
• Vernieri F, Brunelli N, Messina R, et al. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain. 2021;22(1):154.
   PubMed Web of Science ®Google Scholar
• Kanaan S, Hettie G, Loder E, et al. Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia. 2020;40(13):1511–1522.
   PubMed Web of Science ®Google Scholar
• Barbanti P, Aurilia C, Egeo G, et al. Erenumab in the prevention of high-frequency episodic and chronic migraine: erenumab in real life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache. 2021;61(2):363–372.
   PubMed Web of Science ®Google Scholar
• Cheng S, Jenkins B, Limberg N, et al. Erenumab in chronic migraine: an Australian experience. Headache. 2020;60(10):2555–2562.
   PubMed Web of Science ®Google Scholar
• Alex A, Vaughn C, Rayhill M. Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study. Headache. 2020;60(10):2454–2462.
   PubMed Web of Science ®Google Scholar
• Khan K, Arain MI, Asghar MA, et al. Analysis of treatment cost and persistence among migraineurs: a two-year retrospective cohort study in Pakistan. PLoS One. 2021;16(3):e0248761.
   PubMed Web of Science ®Google Scholar